ATX2 Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-7974R-APC-Cy7-100uL |
| Product Name | ATX2 Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat, Dog, Cow, Pig, Horse, Chicken |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human ATX2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 6311 |
| Swiss Prot | Q99700 |
| Subcellular location | Cytoplasm |
| Synonyms | ATX2; SCA2; ASL13; TNRC13; Ataxin-2; Spinocerebellar ataxia type 2 protein; Trinucleotide repeat-containing gene 13 protein; ATXN2 |
| Background | The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ATX2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. ATX2 is caused by expansion of a CAG repeat in the coding region of ATX2. Longer expansions result in earlier onset of the disease. There are four named isoforms. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is ATX2 Polyclonal Antibody, APC-Cy7 Conjugated (bs-7974R-APC-Cy7) validated for, and at what dilution?
bs-7974R-APC-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does ATX2 Polyclonal Antibody, APC-Cy7 Conjugated (bs-7974R-APC-Cy7) react with?
Tested reactivity: Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Human, Rat, Dog, Cow, Pig, Horse, Chicken.
How should bs-7974R-APC-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise ATX2 Polyclonal Antibody, APC-Cy7 Conjugated (bs-7974R-APC-Cy7)?
KLH conjugated synthetic peptide derived from human ATX2
What are the excitation and emission wavelengths of the APC-Cy7 conjugate (bs-7974R-APC-Cy7)?
APC-Cy7 on bs-7974R-APC-Cy7: excitation / emission 650nm/780nm.